25-286 Phase II
A Phase 1/2a, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients with Advanced KRAS G12D-Mutant Solid Tumors
Search Cancer Clinical Trials
Mass General Brigham Cancer Institute offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
21 results
25-531 Phase I
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects with Advanced KRAS Mutant Cancers
24-353 Phase I
A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors
24-649 Phase I
A Phase 1a/1b Study of the pan-KRAS Inhibitor LY4066434 in Participants with KRAS Mutant Solid Tumors
25-370 Phase I
A Phase 1b Study of Neoadjuvant ASP2138 Monotherapy and Investigator’s Choice of Adjuvant Chemotherapy in Participants with Resectable Pancreatic Ductal Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression
22-216 Phase II
A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), or von Hippel-Lindau (VHL) Disease-Associated Tumors
25-587 Phase II
A Phase I/II, open-label, adaptive two-part trial to evaluate the safety, efficacy, optimal dose and pharmacokinetics of BNT326 as monotherapy and in combination with cancer immunotherapies in participants with advanced solid tumors
24-325 Phase II
A Platform Study of RAS(ON) Inhibitors to Treat Patientswith Gastrointestinal Solid tumors
23-242 Phase I
An Open-Label Phase 1 Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of PRTH-101 Alone or in Combination with Pembrolizumab in Adults with Locally Advanced or Metastatic Solid Tumors
25-617 Phase I
First-in-Human, Phase 1 Study of PHN-012, an Antibody Drug Conjugate, in Patients with Advanced Solid Tumors
Showing 1 - 10 of 21 results